Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.


Content Type: External Resource

Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2

Understanding the frequency with which new symptoms and conditions emerge in the months following SARS-CoV-2 infection is important to inform patients’ expectations for recovery and allow health care professionals and health systems to address patients’ needs. Shortness of bre...

   Estimated Time: Coronavirus, COVID-19, Post COVID-19

Long-Term Cardiovascular Outcomes of COVID-19

The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of ...

   Estimated Time: Coronavirus, COVID-19, Post COVID-19

Get The Facts: COVID-19, Myocarditis, and Vaccines (Infographic)

Myocarditis is inflammation of the heart muscle. This can happen after viral infections like COVID-19 and, very rarely, after receiving mRNA COVID-19 vaccines. Most people with myocarditis following vaccination recover completely with rest and simple treatment. However, myocar...

   Estimated Time: Cardiovascular, Coronavirus, COVID-19, Vaccines

PASC Dashboard: Post-Acute Sequelae of SARS-CoV-2 Infections (PASC) Estimates and Insights

The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has undertaken comprehensive efforts to support our call for a national plan to address Post-Acute Sequelae of SARS-CoV-2 infection (PASC or Long COVID) and the millions Americans it is affecting. The PASC D...

   Estimated Time: Coronavirus, COVID-19, Post COVID-19, Statistics

Parallel Pandemics From the Mind of Medicine (Podcast)

This is a podcast series accounting for the parallel pandemics of COVID-19 and clinician burnout, while introducing the story of one undocumented patient who helped to reveal the authentic feelings and values of his healthcare team. With historically high mortality rates in th...

WHO Resource: WHO recommends two new drugs to treat COVID-19

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The first drug, baricitinib, is strongly recommended for pat...

   Estimated Time: Coronavirus, COVID-19

HHS Resource: HHS/ASPR Project ECHO COVID-19 Clinical Rounds

List Serve registration link for upcoming COVID-19 Clinical Rounds and catalog of prior presentations. This initiative supports a series of teleECHO programs that follow the needs of participants based on the trajectory of the pandemic. The aim is to create peer-to-peer learni...

HHS Resource: Federal Response to COVID-19 - Therapeutics Clinical Implementation Guide

HHS Presentation - Topics include: Introduction to COVID-19 Outpatient Therapeutics & Product Selection, Tools to Assist in COVID-19 Outpatient Therapeutic Selection, Overview of Emergency Use Authorizations, Oral Antiviral Indications and Dosing, Provider and Patient EU...

HHS Resource: COVID-19 Therapeutics Locator

The national map below displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority. The locations displayed in the locator have reported stock...

CMS Resource: Coverage of Monoclonal Antibody Products to Treat COVID-19 (Infographic)

Medicare & COVID-19 Monoclonal Antibody Products: Coverage, Coding, Payment and Billing. Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary...

   Estimated Time: Coronavirus, COVID-19, Therapies

CDC Resources: Procedures

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Procedures

   Estimated Time: Coronavirus, COVID-19, Diagnosis and Testing

NIH Resource: The COVID-19 Treatment Guidelines Panel’s Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints

The COVID-19 Treatment Guidelines Panel (the Panel) has recommended several therapeutic agents for the treatment and prevention of SARS-CoV-2 infection in individuals who are at high risk for progression to severe COVID-19. These anti-SARS-CoV-2 therapeutics are of greatest be...

CDC Resources: Epidemiology-Outcomes

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Epidemiology-Outcomes

   Estimated Time: Coronavirus, COVID-19, Statistics

One-Year Outcomes of Postintensive Care Syndrome in Critically Ill Coronavirus Disease 2019 Patients: A Single Institutional Study

From Critical Care Explorations  In this study, the authors found that Patients who suffered critical illness from coronavirus disease 2019 had a high frequency of postintensive care syndrome after 1 year. 

   Estimated Time: 25:16 min Coronavirus, COVID-19

WHO Resource: WHO Therapeutics and COVID-19: living guideline

The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via ...

   Estimated Time: Coronavirus, COVID-19, Therapies

AHA Resource: How a Bold, New Strategy Took on Health Care Inequities During the Pandemic (Blog)

AHA published a new blog post from an LLN member hospital titled,  The Pandemic. “How a Bold, New Strategy Took on Health Care Inequities During the Pandemic,” authored by Luminis Health Chief Diversity Officer Tamiko Stanley.  

FDA Resource: Paxlovid received EUA approval from the FDA

December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years o...

   Estimated Time: Coronavirus, COVID-19, Therapies

FDA Resource: Molnupiravir received EUA approval from the FDA

The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir sh...

   Estimated Time: Coronavirus, COVID-19, Therapies

ATS Resource: Critical Perspective: Bacterial Superinfection in Patients Mechanically Ventilated for COVID-19 Pneumonia (Podcast)

In this “Breathe Easy Critical Perspective” podcast, Dr. Dominique Pepper interviews Dr. Richard Wunderink They discuss Dr. Wunderink's recent publication in the Blue Journal about bacterial superinfection in patients intubated and mechanically ventilated for COVID-19 pneumoni...

AHA Resource: Nurse leaders discuss COVID-19 nursing challenges, solutions (Podcast)

The fourth and current wave of the COVID-19 pandemic has created a worrisome landscape for the nursing profession. Nurses across the country report that they no longer feel celebrated as heroes as they did in the early days of the pandemic. This AHA Podcast covers nurse leader...

   Estimated Time: Coronavirus, COVID-19, Mental Health